AIM ImmunoTech revenue was $140 k in FY, 2019
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 161.0k | 213.0k | 150.0k | 197.0k | 133.0k | 92.0k | 437.0k | 367.0k | 140.0k |
Revenue growth, % | 31% | (32%) | (31%) | ||||||
Cost of goods sold | 1.0m | 2.0m | 1.2m | 1.3m | 1.6m | 1.1m | 1.2m | 884.0k | 893.0k |
Gross profit | (882.0k) | (1.8m) | (1.1m) | (1.1m) | (1.5m) | (1.0m) | (746.0k) | (517.0k) | (753.0k) |
Gross profit Margin, % | (548%) | (834%) | (723%) | (535%) | (1102%) | (1104%) | (171%) | (141%) | (538%) |
R&D expense | 6.7m | 9.5m | 8.4m | 9.0m | 8.0m | 5.1m | 4.1m | 4.8m | 4.7m |
General and administrative expense | 6.7m | 9.1m | 7.7m | 9.1m | 7.1m | 7.7m | 6.6m | 6.2m | 7.0m |
Operating expense total | 13.4m | 18.6m | 16.1m | 18.0m | 15.2m | 12.8m | 10.7m | 11.0m | 11.7m |
EBIT | (14.3m) | (20.3m) | (17.2m) | (19.1m) | (16.6m) | (13.8m) | (11.4m) | (11.5m) | (12.4m) |
EBIT margin, % | (8879%) | (9549%) | (11445%) | (9695%) | (12519%) | (15004%) | (2612%) | (3132%) | (8888%) |
Interest expense | 41.0k | 24.0k | 16.0k | 11.0k | |||||
Interest income | 364.0k | 129.0k | 88.0k | ||||||
Net Income | (9.0m) | (17.4m) | (16.2m) | (17.4m) | (15.2m) | (7.5m) | (8.3m) | (9.8m) | (9.5m) |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (9.0m) | (17.4m) | (16.2m) | (17.4m) | (15.2m) | (7.5m) | (8.3m) | (9.8m) | (9.5m) |
Depreciation and Amortization | 465.0k | 643.0k | 867.0k | 1.1m | 1.2m | 1.1m | 948.0k | 856.0k | 792.0k |
Accounts Receivable | (24.0k) | (1.1m) | 274.0k | ||||||
Inventories | (110.0k) | (579.0k) | (1.3m) | ||||||
Accounts Payable | 424.0k | 860.0k | (617.0k) | 869.0k | (196.0k) | (326.0k) | 566.0k | 166.0k | (207.0k) |
Cash From Operating Activities | (10.1m) | (13.1m) | (16.8m) | (13.9m) | (16.1m) | (7.4m) | (7.9m) | (10.6m) | (9.1m) |
Purchases of PP&E | (1.8m) | (5.8m) | (898.0k) | (504.0k) | (240.0k) | (160.0k) | (20.0k) | (51.0k) | (68.0k) |
Cash From Investing Activities | 8.7m | (16.1m) | 22.3m | 2.5m | 6.4m | 2.9m | 2.7m | 92.0k | (6.1m) |
Long-term Borrowings | (71.0k) | (47.0k) | (45.0k) | (34.0k) | (264.0k) | (340.0k) | |||
Dividends Paid | 388.0k | (135.0k) | |||||||
Cash From Financing Activities | 1.6m | 28.3m | (6.8m) | 12.8m | 9.7m | 4.8m | 4.2m | 9.4m | 16.4m |
Net Change in Cash | 183.0k | (891.0k) | (1.4m) | 1.4m | (41.0k) | 293.0k | (996.0k) | (1.1m) | 1.2m |
Interest Paid | 3.0k | 101.0k | 328.0k |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.1 x |